A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers

Trial Profile

A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Apr 2018

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Trametinib (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CheckMate9N9
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 22 Feb 2018 Planned End Date changed from 23 Nov 2022 to 24 Nov 2022.
    • 22 Feb 2018 Planned primary completion date changed from 20 Sep 2021 to 21 Sep 2021.
    • 25 Jan 2018 Planned End Date changed from 17 Dec 2022 to 23 Nov 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top